|
| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Pancreatic Cancer
|
2017
|
NCI
|
5F31CA203563-02
|
|
Investigating the Role of Novel Drug Target TBK1 in Pancreatic Cancer Pathogenesis
|
BRANNON, ARTHUR
|
UNIVERSITY OF MICHIGAN
|
MI
|
$28,044
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA163489-05
|
|
Characterization of lcmt in Animal Models of Cancer
|
PHILIPS, MARK
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$351,713
|
|
Pancreatic Cancer
|
2017
|
NIAID
|
5R01AI058072-12
|
|
Structural Basis for Chemokine Function
|
VOLKMAN, BRIAN
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$344,250
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R21CA202487-02
|
|
KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic Cancer
|
LI, DONGHUI
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$174,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA051210-25
|
|
Biochemical and molecular studies on NQO1. Design of less toxic Hsp90 inhibitors
|
ROSS, DAVID
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$312,983
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA201318-02
|
|
The Paradoxical Role of mTORC1 in the Growth of Nutrient-deprived Pancreatic Cancer Cells Harboring Ras Mutations
|
THOMPSON, CRAIG
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$339,879
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R35CA210088-01
|
|
The Role of Stem Cells and the Microenvironment in Gastrointestinal Cancers
|
WANG, TIMOTHY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$942,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F31CA180738-04
|
|
Genetic and pharmacological manipulation of system xc in pancreatic cancer
|
BADGLEY, MICHAEL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$44,044
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA200572-02
|
|
PKD1 signaling in the initiation of pancreatic cancer
|
STORZ, PETER
|
MAYO CLINIC JACKSONVILLE
|
FL
|
$357,994
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA193895-02
|
|
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy
|
SLUSHER, BARBARA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$425,618
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA193365-02
|
|
Molecular Imaging of Cachexia in Pancreatic Cancer
|
BHUJWALLA, ZAVER
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$370,575
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R21CA194836-02
|
|
Mouse model to study dependence of pancreatic cancer on Pik3ca for progression
|
LIN, RICHARD
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$169,711
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA123031-09
|
|
Dynamic requirements of Ras signaling during cancer
|
COUNTER, CHRISTOPHER
|
DUKE UNIVERSITY
|
NC
|
$341,999
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA168448-05
|
|
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment
|
YAMAMOTO, MASATO
|
UNIVERSITY OF MINNESOTA
|
MN
|
$315,400
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA202846-02
|
|
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles
|
YANG, LILY
|
EMORY UNIVERSITY
|
GA
|
$411,268
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA184510-03
|
|
Genetic analysis of ras mutation specificity in skin and lung cancer
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$362,512
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA172380-05
|
|
Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology
|
MEEKER, ALAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$335,820
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA174861-04
|
|
Novel Theranostics for Pancreatic Cancer
|
DAVYDOVA, JULIA
|
UNIVERSITY OF MINNESOTA
|
MN
|
$319,031
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA167291-05
|
|
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$493,963
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA183101-03
|
|
Biophotonics to Couple Pancreatic with Upper GI Screening via Ultrathin Endoscopy
|
BACKMAN, VADIM
|
NORTHWESTERN UNIVERSITY
|
IL
|
$634,023
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R03CA201502-02
|
|
Multiplex 'Conditional' Mice for Rapid and Affordable Pre-clinical Testing
|
MORIARITY, BRANDEN
|
UNIVERSITY OF MINNESOTA
|
MN
|
$76,208
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R21CA185962-02
|
|
Pancreatic Cyst Fluid miRNOME for Biomarkers of Pancreatic Cancer
|
SEN, SUBRATA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$173,556
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA192904-03
|
|
Finding Novel Pancreatic Cancer Oncogenes Using an Innovative 3D Culture System
|
BAKER, LINDSEY
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$47,190
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA175772-04
|
|
Targeting tumor-stromal interaction for pancreatic cancer therapy
|
SINGH, AJAY
|
UNIVERSITY OF SOUTH ALABAMA
|
AL
|
$314,363
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA180717-03
|
|
The Characterization of the New Tumor Suppressor USP9X in Pancreatic Cancer
|
HWANG, CHANG-IL
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$63,078
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA196215-02
|
|
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC
|
YAMAMOTO, MASATO
|
UNIVERSITY OF MINNESOTA
|
MN
|
$348,844
|
|
Pancreatic Cancer
|
2017
|
NIAAA
|
5P50AA011999-19
|
8464
|
Animal Core
|
TSUKAMOTO, HIDEKAZU
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$448,224
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P01CA094237-15
|
7522
|
ENGINEERING T CELLS FOR PANCREATIC CANCER
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$254,484
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA200313-02
|
|
K-Ras mutant-specific vulnerabilities for novel pancreatic cancer therapies
|
HOBBS, GUY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$57,066
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA172560-05
|
|
Mechanisms of action of the Smyd3 methyltransferase in cancer cells
|
GOZANI, OR
|
STANFORD UNIVERSITY
|
CA
|
$457,506
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA181360-04
|
|
Clustered semi-competing risks analysis in quality of end-of-life care studies
|
HANEUSE, SEBASTIEN
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
MA
|
$446,179
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA192769-03
|
|
MYC is a critical downstream effector in KRAS-driven pancreatic cancer
|
ALLEN-PETERSEN, BRITTANY
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$60,990
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA183984-03
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$473,915
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA181450-04
|
|
Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy
|
ZEH, HERBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$319,550
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA135650-08
|
|
Predictive Cancer Diagnostics and Therapy Response
|
MOORE, ANNA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$552,368
|
|
Pancreatic Cancer
|
2017
|
NCI
|
2P30CA006516-52
|
5410
|
Program 32: Gastrointestinal Malignancies
|
FUCHS, CHARLES
|
DANA-FARBER CANCER INST
|
MA
|
$42,984
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA192381-03
|
|
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA
|
BREKKEN, ROLF
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$454,817
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1P01CA210944-01
|
5575
|
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$654,726
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA186043-03
|
|
Musashi-mediated control of pancreatic cancer growth and progression
|
REYA, TANNISHTHA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$379,518
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA203108-03
|
|
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic Cancer
|
LI, MIN
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$539,228
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA175747-04
|
|
Mechanisms of PAK1 activation, signaling and tumor resistance
|
DER, CHANNING
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$406,839
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P01CA084203-13
|
5335
|
Core B: Biological Models, Biostatistics, Molecular Pathology and Microscopy
|
BOUMA, BRETT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$159,779
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P01CA084203-13
|
5338
|
Project 2: Endoscopic Photodynamic and Combination Therapy for Local and Metastatic Pancreatic Tumors
|
PEREIRA, STEPHEN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$209,212
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P01CA084203-13
|
5339
|
Project 3: Mechanism-Based Design ofCombination Therapies for Pancreatic Cancer
|
HASAN, TAYYABA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$228,855
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P01CA084203-13
|
5340
|
Project 4: Model-Based Dosimetry and Imaging for PDT
|
POGUE, BRIAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$167,050
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA211176-01
|
|
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer
|
ELSEA, SARAH
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$362,569
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA211878-01
|
|
Common genetically altered pathways as targets for therapy in pancreatic cancer
|
WITKIEWICZ, AGNIESZKA
|
UNIVERSITY OF ARIZONA
|
AZ
|
$351,131
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA172045-04
|
|
Epigenetic regulation of pancreatic cancer
|
HEBROK, MATTHIAS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$328,888
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA211927-01
|
|
Reconstituting human pancreatic cancer development for translational research
|
KIM, SEUNG
|
STANFORD UNIVERSITY
|
CA
|
$515,614
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA212350-01
|
|
Stroma targeted theranostic nanoparticles for pancreatic cancer
|
MCNALLY, LACEY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$354,563
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA212600-01
|
|
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer
|
BRODY, JONATHAN
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$397,605
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA200755-02
|
|
Exploring the Role of Mitochondrial Fission in Pancreatic Tumorigenesis
|
KASHATUS, DAVID
|
UNIVERSITY OF VIRGINIA
|
VA
|
$355,857
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5R01GM105964-04
|
|
The molecular determinants of zinc uptake mediated by hZIP4
|
DEMPSKI, ROBERT
|
WORCESTER POLYTECHNIC INSTITUTE
|
MA
|
$285,769
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA189209-03
|
|
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies
|
MURPHY, WILLIAM
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$365,919
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA192819-03
|
|
A differentiation-based mechanism limiting pancreatic tumor initiation
|
KRAH, NATHAN
|
UNIVERSITY OF UTAH
|
UT
|
$40,653
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R03CA212068-01
|
|
Epigenetic regulation of metabolic rerpogramming in pancreatic cancer
|
TZATSOS, ALEXANDROS
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$79,750
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA131045-07
|
|
ATDC Function in Human Pancreatic Adenocarcinoma
|
SIMEONE, DIANE
|
UNIVERSITY OF MICHIGAN
|
MI
|
$368,125
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA033084-34
|
|
Mechanisms of Murine Turmor Eradication by Immunotherapy
|
GREENBERG, PHILIP
|
UNIVERSITY OF WASHINGTON
|
WA
|
$574,748
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA186662-04
|
|
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
|
ZHANG, RUIWEN
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
TX
|
$480,479
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA213233-01
|
|
Exosomes in Cancer Therapy
|
KALLURI, RAGHU
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$384,147
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5P20GM109024-02
|
5952
|
Administrative Core: Center for Diagnostic and Therapeutic Strategies in Pancreatic Cancer
|
MALLIK, SANKU
|
NORTH DAKOTA STATE UNIVERSITY
|
ND
|
$643,945
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5P20GM109024-02
|
5953
|
Animal Core Facility
|
GUO, BIN
|
NORTH DAKOTA STATE UNIVERSITY
|
ND
|
$380,400
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5P20GM109024-02
|
5954
|
Nanoparticle-Powered Chemiluminescent Lateral Flow Biosensor Array for Early Diagnosis of Pancreatic Cancer
|
LIU, GUODONG
|
NORTH DAKOTA STATE UNIVERSITY
|
ND
|
$213,349
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5P20GM109024-02
|
5955
|
Effects of salinomycin and binding target proteins in pancreatic cancer
|
WU, ERXI
|
NORTH DAKOTA STATE UNIVERSITY
|
ND
|
$212,721
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5P20GM109024-02
|
5956
|
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine
|
REINDL, KATIE
|
NORTH DAKOTA STATE UNIVERSITY
|
ND
|
$212,806
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5P20GM109024-02
|
5957
|
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors
|
LECLERC, ESTELLE
|
NORTH DAKOTA STATE UNIVERSITY
|
ND
|
$212,747
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA175315-04
|
|
MicroRNA-1291 in Regulation of Xenobiotic Disposition and Cell Differentiation
|
YU, AIMING
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$310,326
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
5R01DK055489-18
|
|
Pancreas Transcription Factors and Disease Model Systems
|
KONIECZNY, STEPHEN
|
PURDUE UNIVERSITY
|
IN
|
$322,868
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R21CA212827-01
|
|
Single-molecule mechanical detection of protein and microRNA cancer biomarkers
|
WONG, WESLEY
|
BOSTON CHILDREN'S HOSPITAL
|
MA
|
$267,258
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA194593-03
|
|
PQB3: Mechanisms & Targeting of Sonic Hedgehog Signaling in Muscle Wasting of Cancer Cachexia
|
ZIMMERS, TERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$355,258
|
|
Pancreatic Cancer
|
2017
|
NIAID
|
5R21AI124687-02
|
|
Stromal IL-6/Jak-STAT signaling and pancreatitis
|
OSTROWSKI, MICHAEL
|
OHIO STATE UNIVERSITY
|
OH
|
$192,500
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA168611-05
|
|
Toll-like Receptor Regulation of Pancreatic Tumorigenesis
|
MILLER, GEORGE
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$351,713
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA178856-04
|
|
Menin-mediated epigenetic tumor suppression
|
HUA, XIANXIN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$332,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA177670-04
|
|
REPROGRAMMING THE METASTATIC MICROENVIRONMENT OF PANCREATIC CANCER THROUGH CSF1R
|
DENARDO, DAVID
|
WASHINGTON UNIVERSITY
|
MO
|
$316,438
|
|
Pancreatic Cancer
|
2017
|
NCI
|
2R01CA157490-07A1
|
|
Investigating the Role of Autophagy in Pancreatic Cancer Radiation Resistance
|
KIMMELMAN, ALEC
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$402,563
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA203238-02
|
|
Mechanisms of Escape from TGFβ Tumor Suppression in the Pancreas
|
HUANG, YUN-HAN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$49,044
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA203890-02
|
|
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
|
DENARDO, DAVID
|
WASHINGTON UNIVERSITY
|
MO
|
$348,844
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA206105-01A1
|
|
Regulation of Pancreatic Oncogenesis by the Gut Microbiome
|
MILLER, GEORGE
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$375,150
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA196124-03
|
|
Pro- and anti-phagocytic signals on pancreatic cancer regulate tumor macrophages
|
LIU, MINGEN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$30,917
|
|
Pancreatic Cancer
|
2017
|
NCI
|
2R01CA163764-06
|
|
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49
|
HAWKINS, WILLIAM
|
WASHINGTON UNIVERSITY
|
MO
|
$381,250
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA188134-01A1
|
|
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$510,684
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA204969-01A1
|
|
Uncovering Role of Exosomes in Regulating Pancreatic Cancer Cell Metabolism
|
NAGRATH, DEEPAK
|
UNIVERSITY OF MICHIGAN
|
MI
|
$332,357
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA204916-01A1
|
|
Beyond apoptosis, Bcl-xL in tumor metastasis
|
DU, YI-CHIEH NANCY
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$406,557
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R35CA197709-02
|
|
New Ways of Targeting K-Ras
|
MCCORMICK, FRANK
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$918,748
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA184051-03
|
|
Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer
|
CULLEN, JOSEPH
|
UNIVERSITY OF IOWA
|
IA
|
$348,844
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5K07CA204201-02
|
|
Video Informed Consent Tools to Improve Care for Patients With Advanced Pancreatic Cancer
|
ENZINGER, ANDREA
|
DANA-FARBER CANCER INST
|
MA
|
$176,231
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA213278-01
|
|
Reprogramming Tumor Microenvironment by Nanoparticle
|
MUKHERJEE, PRIYABRATA
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$338,550
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
1K08DK109492-01A1
|
|
The role of progenitor cells in pancreatic acinar renewal and pre-malignant progression
|
MADDIPATI, RAVIKANTH
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$170,196
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA188300-03
|
|
Motion Management of Pancreatic Cancer in MRI-Guided Radiotherapy
|
SHENG, KE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$337,028
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA154823-06
|
|
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)
|
KLEIN, ALISON
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$646,350
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA197916-02
|
|
Targeting macrophages for immunotherapy in pancreatic cancer
|
BEATTY, GREGORY
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$368,288
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
5R01DK061220-13
|
|
Transcriptional Regulators of the Exocrine Pancreatic Phenotype
|
MACDONALD, RAYMOND
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$473,738
|
|
Pancreatic Cancer
|
2017
|
NCI
|
2R01CA150190-06A1
|
|
Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to Bedside
|
MUKHOPADHYAY, DEBABRATA
|
MAYO CLINIC JACKSONVILLE
|
FL
|
$598,146
|
|
Pancreatic Cancer
|
2017
|
NHGRI
|
1UM1HG009426-01
|
|
Center for Functional Validation and Evaluation of ENCODE Enhancer Regions
|
WHITE, KEVIN
|
UNIVERSITY OF CHICAGO
|
IL
|
$654,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA196040-02
|
|
Structural basis of chemokine receptor signaling in tumor progression
|
KLEIST, ANDREW
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$46,044
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA190717-03
|
|
Alternatively Spliced Tissue Factor and Pathobiology of Pancreatic Cancer
|
BOGDANOV, VLADIMIR
|
UNIVERSITY OF CINCINNATI
|
OH
|
$276,298
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA196941-02
|
|
Novel Signaling Pathways Regulating Pancreatic Cancer Pathogenesis
|
WANG, HUAMIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA167535-05
|
|
Novel Nanoparticle Therapy for Pancreatic Cancer
|
MATTERS, GAIL
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$313,134
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA186286-04
|
|
Pancreatic Cancer Cell Mechanics and Imaging
|
KONSTANTOPOULOS, KONSTANTINOS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$426,010
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA200240-02
|
|
Role of Nix in pancreatic ductal adenocarcinoma
|
ALAGESAN, BRINDA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$49,044
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA097022-15
|
|
Survival Mechanisms of Invasive Carcinoma Cells
|
KLEMKE, RICHARD
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$351,599
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA154649-07
|
|
The role of entosis in human cancers
|
OVERHOLTZER, MICHAEL
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$397,329
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA178445-03
|
|
The role of wild-type KRAS in the context of tumor profession and metastasis
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$462,118
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA198128-02
|
|
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer
|
WILLIAMS, TERENCE
|
OHIO STATE UNIVERSITY
|
OH
|
$397,192
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA172233-05
|
|
Molecular Mediators of Pancreatic Cancer Invasion and Progression
|
XIE, KEPING
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$332,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA187923-03
|
|
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus
|
ZHANG, XIAOLIU
|
UNIVERSITY OF HOUSTON
|
TX
|
$344,023
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA075059-19
|
|
Dysregulation of TGF Beta Action Pancreatic Cancer
|
KORC, MURRAY
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$441,940
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA194941-02
|
|
Suppression of pancreatic tumorigenesis by the PTF1 transcription factor network
|
MURTAUGH, LEWIS
|
UNIVERSITY OF UTAH
|
UT
|
$320,718
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA152653-07
|
|
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers
|
HAAB, BRIAN
|
VAN ANDEL RESEARCH INSTITUTE
|
MI
|
$554,248
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA180949-04
|
|
Early detection of pancreatic cancer in diabetics
|
CHEN, RU
|
UNIVERSITY OF WASHINGTON
|
WA
|
$587,611
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P30CA086862-17
|
7670
|
Program 1: Cancer Genes and Pathways
|
QUELLE, DAWN
|
UNIVERSITY OF IOWA
|
IA
|
$16,730
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
5R01DK107767-02
|
|
Omega-3 derived epoxy fatty acids and sEH in pancreatitis-induced carcinogenesis
|
YANG, GUANG-YU
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$481,828
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
5R01GM113166-03
|
|
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer
|
MAHATO, RAM
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$356,087
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1F32CA213764-01
|
|
The role of neuroendocrine transdifferentiation of pancreatic cancer cells on tumor progression and chemoresistance.
|
MORRISON JOLY, MEGHAN
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$56,694
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA185357-04
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$398,393
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1F32CA213810-01
|
|
Understanding metabolic pathways that support redox homeostasis in cancer
|
MUIR, ALEXANDER
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$56,694
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1F30CA213883-01
|
|
Identifying novel effectors of oncogenic Kras in pancreatic cells via proximity labelling
|
CHENG, DEREK
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$33,839
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1F30CA213916-01
|
|
FOLFOX-induced kinome reprogramming in pancreatic cancer tumor xenografts
|
LIPNER, MATTHEW
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$30,078
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA208272-01A1
|
|
Developing novel combination therapies for pancreatic cancer
|
YOON, KARINA
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$339,694
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA200078-02
|
|
Chemical genetic investigation of metastatic seeding in pancreatic ductal adenocarcinoma using novel multiplexed in vivo screening
|
SCHULZE, CHRISTOPHER
|
STANFORD UNIVERSITY
|
CA
|
$4,565
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA196228-03
|
|
The Role of post-translational activation of Myc in pancreatic cancer
|
SEARS, ROSALIE
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$390,191
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA202917-01A1
|
|
JAK1 Signaling in Pancreatic Cancer Initiation and Progression
|
WAGNER, KAY-UWE
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$340,193
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA184926-04
|
|
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
|
JAFFEE, ELIZABETH
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$765,544
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA034610-35
|
|
TGFB-SMAD Signaling in Stem Cell Differentiation and Tumor Suppression
|
MASSAGUE, JOAN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$468,594
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA169281-05
|
|
Targeting Stromal Collagen in Pancreatic Cancer
|
HAN, HAIYONG
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
AZ
|
$386,727
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA179645-04
|
|
Mechanisms and targeting of SWI/SNF alterations in pancreatic cancer
|
POLLACK, JONATHAN
|
STANFORD UNIVERSITY
|
CA
|
$333,139
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA210439-01A1
|
|
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer
|
SINGH, PANKAJ
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$454,065
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA206234-02
|
|
Exploring BCL-XL addiction in pancreatic ductal adenocarcinoma
|
SODERQUIST, RYAN
|
DUKE UNIVERSITY
|
NC
|
$57,066
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R44CA203052-02
|
|
LASER TISSUE WELDING: BREACHING BARRIERS IN THE SURGICAL MANAGEMENT OF THE PANCREAS
|
WADIA, YASMIN
|
LASER TISSUE WELDING, INC.
|
TX
|
$500,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA172431-05
|
|
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH
|
YANG, GUANG-YU
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$320,338
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA196286-03
|
|
Validation of pancreatic cancer biomarkers in large prospective cohorts
|
LOKSHIN, ANNA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$417,779
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA176828-05
|
|
Using Markers to Improve Pancreatic Cancer Screening
|
GOGGINS, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$416,661
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA206444-02
|
|
Rac1 GTPase in tumorigenesis and progression of pancreatic cancer
|
OUELLETTE, MICHEL
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$374,745
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA198090-02
|
|
Integrated Signaling in Pancreatic Cancer Progression
|
XIE, KEPING
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA169702-05
|
|
Annexin A2 as a mediator of pancreatic cancer metastases
|
ZHENG, LEI
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$336,150
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA204228-02
|
|
Comprehensive genetic dissection of druggable KRAS targets
|
LEACH, STEVEN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$392,078
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F31CA206416-02
|
|
Stem cell signals in pancreatic adenocarcinoma metastasis and therapy resistance
|
LYTLE, NIKKI
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$37,905
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA200468-02
|
|
A Clinical Validation Center for Early Detection of Pancreatic Cancer
|
MAITRA, ANIRBAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$1,759,344
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA193887-02
|
|
Targeting extracellular matrix-cancer stem cell interactions in pancreatic cancer
|
MATSUI, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$370,575
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA082683-18
|
|
Signal Transduction by Tyrosine Phosphorylation
|
HUNTER, TONY
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
CA
|
$674,327
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA197999-02
|
|
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
|
NATARAJAN, AMARNATH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$344,094
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA187090-04
|
|
The Yap-Tead transcriptional complex in Kras-induced Pancreatic Ductal Adenocarci
|
YI, CHUNLING
|
GEORGETOWN UNIVERSITY
|
DC
|
$322,663
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA196087-02
|
|
TSPO-PET to Image Pancreatic Cancer and High-Risk Precursor Lesions
|
WATCHMAKER, JENNIFER
|
VANDERBILT UNIVERSITY
|
TN
|
$44,044
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA182869-03
|
|
The role of DCLK1 in the initiation of pancreatic ductal adenocarcinoma
|
HOUCHEN, COURTNEY
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$345,918
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA168863-05
|
|
CCR2 BLOCKADE IN HUMAN PANCREATIC CANCER
|
LINEHAN, DAVID
|
UNIVERSITY OF ROCHESTER
|
NY
|
$319,377
|
|
Pancreatic Cancer
|
2017
|
OD
|
1S10OD023659-01
|
|
Mass Spectrometer For Small Molecule Analysis
|
NEUBERT, THOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$595,890
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F31CA206233-02
|
|
High-Throughput Generation of Pancreatic Organoids with Controlled Stromal Milieus using Microraft-Based Cell Sorting
|
DISALVO, MATTHEW
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$34,866
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA200466-02
|
|
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms
|
BRAND, RANDALL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$1,537,769
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
7R01DK052913-18
|
|
The Role of Zinc Finger Cofactors in Pancreatic Cell Growth
|
URRUTIA, RAUL
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$346,500
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA206240-02
|
|
Mechanisms of Pancreatic Carcinogenesis
|
HE, PING
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$31,678
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA124586-10
|
|
Kras-Induced Cellular Plasticity in Pancreatic Cancer
|
KONIECZNY, STEPHEN
|
PURDUE UNIVERSITY
|
IN
|
$312,367
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA169086-05
|
|
PDG Links Stem Cell Niche to Pancreatic Epithelial Renewal, Repair and Cancer
|
THAYER, SARAH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$312,288
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA189793-04
|
|
Design and Development of a Small Molecule-controlled Activator of RAS
|
ROSE, JOHN
|
UNIVERSITY OF WASHINGTON
|
WA
|
$43,144
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P01CA067166-20
|
7501
|
The Role of Ire1 in Modulating the Response of Tumors to Hypoxia and Radiation
|
KOONG, ALBERT
|
STANFORD UNIVERSITY
|
CA
|
$204,282
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R33CA206907-01A1
|
|
Rapid unbiased isolation and in situ RNA analysis of circulating tumor cells using a magnetic micropore-based diagnostic chip
|
ISSADORE, DAVID
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$381,612
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1U01CA210020-01A1
|
|
Molecular Imaging Methods for the Detection of Pancreatic Ductal Adenocarcinoma
|
WILLMANN, JUERGEN
|
STANFORD UNIVERSITY
|
CA
|
$603,260
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1U01CA214254-01
|
|
Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
TX
|
$1,075,356
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA207189-02
|
|
Regulation of Nutrient Stress-Induced Macropinocytosis in Pancreatic Ductal Adenocarcinoma
|
COMMISSO, COSIMO
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
|
CA
|
$446,063
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1U01CA210240-01A1
|
|
Pancreatic Cancer Detection Consortium
|
HOLLINGSWORTH, MICHAEL
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$1,761,905
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R33CA204704-01A1
|
|
Multiplex FRET Imaging of Kinase-Epigenome Interregulations in Live Cancer Cells
|
WANG, YINGXIAO
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$376,821
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA178960-04
|
|
Targeting pancreatic cancer energy metabolism, tumor growth, and metastasis
|
DWINELL, MICHAEL
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$515,751
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5K12CA090628-17
|
|
Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
|
JATOI, AMINAH
|
MAYO CLINIC ROCHESTER
|
MN
|
$810,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA198095-02
|
|
Novel Strategies for Precision T-cell Therapies
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$520,564
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P30CA056036-18
|
7226
|
Gastrointestinal Cancer
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$38,251
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA054358-24
|
|
Epigenetic Drivers of Cancer Progression
|
FEINBERG, ANDREW
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$422,743
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA200301-03
|
|
Mechanistic and Informatics Based Analysis of STAT1 Actions in Pancreatic Cancer
|
CRAVEN, KELLY
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$48,053
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA136526-08
|
|
Mechanism of Pancreatic Carcinogenesis
|
FERNANDEZ-ZAPICO, MARTIN
|
MAYO CLINIC ROCHESTER
|
MN
|
$344,108
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA200278-03
|
|
Novel BPTES Analogs for the Treatment of Pancreatic Cancer
|
ZIMMERMANN, SARAH
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$12,629
|
|
Pancreatic Cancer
|
2017
|
NHGRI
|
5F31HG008912-02
|
|
Computational Modeling of Heterogeneous Gene Expression in Single Cells
|
WELCH, JOSHUA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$33,727
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA188252-03
|
|
ROS-targeted therapy for pancreatic cancer
|
NEAMATI, NOURI
|
UNIVERSITY OF MICHIGAN
|
MI
|
$562,471
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA196120-03
|
|
A cell-based liquid biopsy approach for early pancreatic cancer detection
|
BHAGWAT, NEHA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$57,066
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA215607-01
|
|
Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer
|
OLIVE, KENNETH
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$404,558
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R21CA202745-02
|
|
Dim light at night alters pancreatic cell signaling and predisposes to pancreatic adenocarcinoma
|
NELSON, RANDY
|
OHIO STATE UNIVERSITY
|
OH
|
$167,475
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
5R01DK106266-04
|
|
Development, cellular plasticity and homeostasis of the exocrine pancreas
|
SOSA-PINEDA, BEATRIZ
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$336,725
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1U24CA209996-01A1
|
|
Building protected data sharing networks to advance cancer risk assessment and treatment
|
FOSTER, IAN
|
UNIVERSITY OF CHICAGO
|
IL
|
$805,856
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA191191-03
|
|
IDO2 Targeting in Pancreatic Cancer
|
PRENDERGAST, GEORGE
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
PA
|
$391,418
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R21CA215860-01
|
|
CEST MRI assessment of tumor vascular permeability using non-labeled dextrans
|
LIU, GUANSHU
|
HUGO W. MOSER RES INST KENNEDY KRIEGER
|
MD
|
$175,782
|
|
Pancreatic Cancer
|
2017
|
NIBIB
|
5R01EB017853-04
|
|
Polymeric Nanomedicines of Small Molecules and miRNA for Treating Pancreatic Canc
|
MAHATO, RAM
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$338,594
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA209798-01A1
|
|
Investigating the cause of racial/ethnic disparity in pancreatic cancer incidence
|
SETIAWAN, VERONICA
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$395,145
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA174294-05
|
|
Multifunctional immunoPET tracers for pancreatic and prostate cancer
|
WU, ANNA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$444,176
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA186338-03
|
|
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer
|
LI, MIN
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$342,938
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R21CA198265-02
|
|
New HuR inhibitor against pancreatic cancer EMT and CSCs
|
CHEN, QI
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$166,388
|
|
Pancreatic Cancer
|
2017
|
NCI
|
2R01CA154451-04A1
|
|
Ultrasound-enhanced drug penetration for treatment of pancreatic cancer
|
HWANG, JOO
|
UNIVERSITY OF WASHINGTON
|
WA
|
$498,703
|
|
Pancreatic Cancer
|
2017
|
NIBIB
|
1R01EB022230-01A1
|
|
Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.
|
CHOI, HAK SOO
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$676,225
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA124723-10
|
|
The Inhibition of HSP70 Induces Apoptosis in Pancreatic Cancer Cells
|
SALUJA, ASHOK
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$282,901
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA177857-05
|
|
Role of Neurogenic Inflammation in Pancreatic Cancer
|
DAVIS, BRIAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$418,087
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA210553-02
|
|
Image-guided ultrasound therapy and drug delivery in pancreatic cancer
|
FERRARA, KATHERINE
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$636,467
|
|
Pancreatic Cancer
|
2017
|
NIBIB
|
5R21EB022770-02
|
|
High Sensitivity Molecular Ultrasound Imaging in Pancreatic Cancer
|
WILLMANN, JUERGEN
|
STANFORD UNIVERSITY
|
CA
|
$200,802
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R21CA205094-01A1
|
|
Primers: Combining Radiotherapy and Immunotherapy using next genertaion radiotherapy biomaterials
|
NGWA, WILFRED
|
DANA-FARBER CANCER INST
|
MA
|
$229,187
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA210192-02
|
|
Targeted Nanotherapy for Pancreatic Cancer
|
CHAUHAN, SUBHASH
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$347,700
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA184274-04
|
|
Functional Significance of CD133 in Pancreatic Cancer
|
BANERJEE, SULAGNA
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$318,513
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA194321-02
|
|
Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer
|
HUMM, JOHN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$660,603
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA172152-06
|
|
Role of the SWI/SNF complex in tumor suppression
|
ROBERTS, CHARLES
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$357,826
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA201226-02
|
|
High Throughput Screening to Discover Chemical Inhibitors of Quiescin Sulfhydryl Oxidase 1
|
FAIGEL, DOUGLAS
|
MAYO CLINIC ARIZONA
|
AZ
|
$678,423
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R21CA206013-01A1
|
|
(PQ1) Cellular senescence as an initiating event in malignant transformation
|
DAVID, GREGORY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$203,400
|
|
Pancreatic Cancer
|
2017
|
NIGMS
|
2R15GM110632-02
|
|
Label-Free Nanopore Biosensor for Rapid, Ultrasensitive, and Multiplex Detection of Protease Activities
|
GUAN, XIYUN
|
ILLINOIS INSTITUTE OF TECHNOLOGY
|
IL
|
$422,520
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA195586-03
|
|
Targeted Radiation Therapy for Pancreatic Cancer
|
BATRA, SURINDER
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$435,945
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA197296-03
|
|
Reprogramming the pancreatic tumor microenvironment with immunotherapy
|
ZHENG, LEI
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$429,841
|
|
Pancreatic Cancer
|
2017
|
NCI
|
3R01HD065800-07S1
|
|
Mechanisms Controlling Epithelial Homeostasis
|
O'REILLY, ALANA
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$214,199
|
|
Pancreatic Cancer
|
2017
|
NICHD
|
3R01HD065800-07S1
|
|
Mechanisms Controlling Epithelial Homeostasis
|
O'REILLY, ALANA
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$1
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA182311-04
|
|
High dose radiation therapy to direct immune responses to pancreatic cancer
|
GOUGH, MICHAEL
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
OR
|
$321,625
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5K08CA208016-02
|
|
Elucidating KRAS-specific vulnerabilities in pancreatic cancer
|
MUZUMDAR, MANDAR
|
DANA-FARBER CANCER INST
|
MA
|
$37,557
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA208514-02
|
|
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells
|
PAULOS, CHRYSTAL
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$345,257
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA207236-01A1
|
|
Fasting Protects Small Intestinal Stem Cells from Lethal DNA Damage: Mechanistic Insight and Preclinical Translation
|
PIWNICA-WORMS, HELEN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$482,853
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA181385-04
|
|
Stellate cells and their progenitor precursors in pancreas cancer progression
|
PROVENZANO, PAOLO
|
UNIVERSITY OF MINNESOTA
|
MN
|
$308,990
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5K99CA204725-02
|
|
Exploring Glycobiology and Discovering Biomarkers for Pancreatic Cancer
|
ENGLE, DANNIELLE
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$128,235
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA181244-04
|
|
Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing
|
SCHEET, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$1,028,501
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R03CA208510-02
|
|
Interpreting limits to nanoparticle delivery in high-stroma low-perfusion tumors
|
RUSSELL, STEWART
|
DARTMOUTH COLLEGE
|
NH
|
$81,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA207643-02
|
|
Real-time monitoring of circulating pancreatic tumor cells and clusters
|
CARPENTER, ERICA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$522,167
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA200007-03
|
|
Multiplexed imaging of biliary intra-epithelial neoplasia
|
SEIBEL, ERIC
|
UNIVERSITY OF WASHINGTON
|
WA
|
$569,599
|
|
Pancreatic Cancer
|
2017
|
NIAMS
|
2R01AR060209-06A1
|
|
FoxO signaling and skeletal muscle atrophy
|
JUDGE, ANDREW
|
UNIVERSITY OF FLORIDA
|
FL
|
$397,595
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F30CA210587-02
|
|
Mechanism behind CCL21/CCR7-mediated pancreatic cancer progression
|
MOUSSOURAS, NATASHA
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$46,044
|
|
Pancreatic Cancer
|
2017
|
NIBIB
|
5F31EB022414-02
|
|
In-vivo characterization of pancreatic field carcinogenesis using spatially resolved reflectance measurements via a fiber optic probe
|
ESHEIN, ADAM
|
NORTHWESTERN UNIVERSITY
|
IL
|
$38,012
|
|
Pancreatic Cancer
|
2017
|
NCI
|
7R01CA178627-04
|
|
Novel Experimental Therapeutics for Pancreatic Cancer
|
LOMBERK, GWEN
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$319,550
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R21CA209536-02
|
|
Targeting cytokine mediated CREB activation in pancreatic cancer
|
NAGATHIHALLI, NAGARAJ
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$166,931
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA151588-07
|
|
Mechanisms of Pancreatic Inflammation, Tissue Repair and Carcinogenesis
|
PASCA DI MAGLIANO, MARINA
|
UNIVERSITY OF MICHIGAN
|
MI
|
$342,662
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA208335-01A1
|
|
Label free microfluidic isolation, characterization and ex vivo expansion of CTCs
|
NAGRATH, SUNITHA
|
UNIVERSITY OF MICHIGAN
|
MI
|
$554,517
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
1R01DK110361-01A1
|
|
The Hippo signaling pathway in pancreatic epithelial cells orchestrate the inflammatory response R01
|
WANG, PEI
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
TX
|
$339,581
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA208401-01A1
|
|
Protein and proteolytic activity biomarkers of early stage pancreatic cancer
|
TEMPST, PAUL
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$642,526
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA208108-01A1
|
|
MUC16 in Pancreatic Cancer Progression and Metastasis
|
RADHAKRISHNAN, PRAKASH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$345,965
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA042978-31
|
|
Biological Activity of Ras Oncogenes
|
DER, CHANNING
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$349,678
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F31CA196329-02
|
|
Tumor-associated Physiological Changes Arising from Ras-induced Mitochondrial Fission
|
NASCIMENTO, ALDO
|
UNIVERSITY OF VIRGINIA
|
VA
|
$31,376
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA198913-03
|
|
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy
|
YANG, LILY
|
EMORY UNIVERSITY
|
GA
|
$595,122
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5K08CA201581-02
|
|
Role of Interleukin-22 and Innate Lymphoid Cells in Pancreas Cancer Initiation and Progression
|
FRANKEL, TIMOTHY
|
UNIVERSITY OF MICHIGAN
|
MI
|
$106,110
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1U01CA216449-01
|
|
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response
|
LAWRENCE, THEODORE
|
UNIVERSITY OF MICHIGAN
|
MI
|
$578,379
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA210171-02
|
|
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
|
WOLPIN, BRIAN
|
DANA-FARBER CANCER INST
|
MA
|
$794,139
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA104125-13
|
|
Cytoskeletal Dynamics in Pancreatic Cancer Metastasis
|
MC NIVEN, MARK
|
MAYO CLINIC ROCHESTER
|
MN
|
$299,389
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5K08CA172676-05
|
|
Exploration of a Mutant p53 Reactivating Compound
|
CARPIZO, DARREN
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
NJ
|
$158,958
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA195733-03
|
|
Employing mouse models to translate early detection of pancreas cancer
|
KALLURI, RAGHU
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$540,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P50CA127003-10
|
7437
|
Administration, Evaluation, and Planning
|
FUCHS, CHARLES
|
DANA-FARBER CANCER INST
|
MA
|
$190,670
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA210138-02
|
|
Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer
|
PETERSEN, GLORIA
|
MAYO CLINIC ROCHESTER
|
MN
|
$898,049
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA207031-01A1
|
|
The molecular mechanisms of metabolism reprogramming in mutant Kras/Ink4a-driven pancreatic ductal adenocarcinoma
|
CHIAO, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA209886-02
|
|
MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer
|
ZHANG, ZHUOLI
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$352,556
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA210170-02
|
|
Using markers to improve pancreatic cancer screening and surveillance
|
GOGGINS, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$953,081
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA206069-02
|
|
Development of Targeted Nanotechnology Platform for Pancreatic Cancer
|
CHAUHAN, SUBHASH
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$347,700
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5K22CA178309-03
|
|
Parental Exposure to High Fats Diets and Risk of Pancreatic Cancer in the Offspri
|
DE ASSIS, SONIA
|
GEORGETOWN UNIVERSITY
|
DC
|
$153,035
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R35CA197591-03
|
|
Integrative approaches to elucidate p53 transcriptional networks during carcinogenesis
|
ATTARDI, LAURA
|
STANFORD UNIVERSITY
|
CA
|
$975,963
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5U01CA199235-03
|
|
Identification of synthetic lethal interactors in pancreatic cancer
|
DER, CHANNING
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$340,086
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5F32CA210421-02
|
|
Understanding cell intrinsic and context dependent metabolic adaptations of cancer cell
|
DANAI, LAURA
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$56,694
|
|
Pancreatic Cancer
|
2017
|
NCI
|
1R01CA216853-01
|
|
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer
|
SINGH, PANKAJ
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$478,728
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P30CA036727-31
|
5713
|
Planning and Evaluation
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$25,585
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P30CA036727-31
|
5727
|
Gastrointestinal Cancer (GIC)
|
BLACK, JENNIFER
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$68,219
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA186885-04
|
|
Targeting BET Bromodomain in Pancreatic Cancer
|
MUNSHI, HIDAYATULLAH
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$320,588
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA195651-03
|
|
Clinical Significance of Pancreatic Cancer Differentiation and Dedifferentiation
|
XIE, KEPING
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Pancreatic Cancer
|
2017
|
NIAAA
|
5R13AA020691-07
|
|
International Symposium of ALPD and Cirrhosis
|
TSUKAMOTO, HIDEKAZU
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$5,000
|
|
Pancreatic Cancer
|
2017
|
NIDDK
|
5K08DK107781-02
|
|
Characterization of the Molecular Determinants of High-Grade Dysplasia in Pancreatic Cancer Precursor Lesions
|
WOOD, LAURA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$171,720
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R44CA174025-03
|
|
Development of Monoclonal Antibodies to Treat Pancreatic Cancer
|
SUREBAN, SRIPATHI
|
COARE BIOTECHNOLOGY, INC.
|
OK
|
$1,094,011
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5R01CA178015-04
|
|
Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis
|
COLLISSON, ERIC
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$295,065
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P50CA196510-02
|
8213
|
Core A: Administrative Core
|
HAWKINS, WILLIAM
|
WASHINGTON UNIVERSITY
|
MO
|
$151,908
|
|
Pancreatic Cancer
|
2017
|
NCI
|
5P50CA196510-02
|
8214
|
Core B: Biospecimen Core
|
FIELDS, RYAN
|
WASHINGTON UNIVERSITY
|
MO
|
$300,637
|
|
